Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VECTRA-01: AZD2265 vs Standard of Care in mCRPC
NCT07611110Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- May 2026
- Primary completion
- Jun 2029
- Countries
- 24
01
Overview
A Phase 3 trial of palacaparib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by AstraZeneca. Started May 2026; status: recruiting.
02
Drugs
palacaparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07611110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07611110.